Influenza is an acute respiratory illness caused by influenza A or B viruses that occurs in epidemics worldwide, mainly during the winter season. It is associated with increased morbidity and mortality in certain high-risk populations such as elderly, patients with comorbidities or infants.
The neuraminidase inhibitor oseltamivir phosphate is active against both influenza A and B and can be administered for the treatment and prevention of influenza.
The demand for oseltamivir phosphate is currently high. In addition to the commercially available medication, there is a need for the oral liquid dose form because some patient groups are in need of tailored medication.
Oseltamivir phosphate compounded in SyrSpend® SF PH4 has a proven beyond use date of at least 90 days for 15 mg/ml*. In addition, oseltamivir phosphate 6 mg/ml in SyrSpend® SF PH4 is currently compatible for at least 60 days and the study is still running until 90 days.
The compounding instructions for 15 mg/ml and 6 mg/ml oseltamivir phosphate in SyrSpend® SF PH4 can be found in our free online formulations database Compounding Matters.